• Gastric Cancer Assembloids: Tumor–Stroma Drug Response

  2026-09-29

  The reference study develops patient-derived gastric cancer assembloids by combining tumor organoids with matched stromal cell subpopulations. Its findings show that stromal composition changes gene expression and drug sensitivity, supporting more physiologically relevant studies of tumor biology, resistance, and personalized treatment.

• Prednisone in Immune Assays: G1 Arrest to Readouts

  2026-09-29

  Prednisone is a synthetic corticosteroid used to model lymphocyte suppression, G1 arrest, cytokine signaling, and apoptosis. This guide adds a matrix-aware assay strategy inspired by recent LC–MS/MS research on digestive transformations, helping researchers connect compound handling with more interpretable immune-cell data.

• (S)-(+)-Dimethindene maleate: M2 Workflow

  2026-09-28

  (S)-(+)-Dimethindene maleate is a research reagent for probing M2 muscarinic receptor antagonism while accounting for additional histamine H1 activity. This guide covers salt-aware preparation, controls, and QC for autonomic, cardiovascular, and respiratory assays; it is not intended for diagnostic, therapeutic, or clinical use.

• Bromodomain Inhibitor, (+)-JQ1: Evidence & Use

  2026-09-28

  Bromodomain Inhibitor, (+)-JQ1 is a BET bromodomain inhibitor that competitively targets acetyl-lysine binding sites, including BRD4 bromodomains 1 and 2. Research evidence connects JQ1 treatment with reduced KLF6 expression and adipogenesis in human adipose-derived stem cells, while other reported applications remain model-specific and preclinical.

• Grazoprevir hydrate for Reliable HCV Assays

  2026-09-27

  A scenario-driven guide to using Grazoprevir hydrate (SKU C8713) in HCV antiviral and cell-viability workflows. It explains assay controls, DMSO compatibility, genotype-specific potency context, and practical criteria for evaluating research compounds without confusing antiviral activity with cytotoxicity.

• Machine Learning Predicts mRNA Vaccine LNP Performance

  2026-09-26

  A LightGBM model trained on 325 mRNA vaccine lipid nanoparticle formulations predicted IgG responses and highlighted ionizable-lipid substructures associated with performance. Mouse experiments and molecular dynamics provided complementary checks, illustrating how computational screening can guide formulation research without replacing experimental validation.

• Palomid 529: Testing the RCN2–AKT Axis in ESCC

  2026-09-25

  Explore how Palomid 529 (P529), a dual mTORC1/2 inhibitor, can help test signaling hypotheses raised by new ESCC research. This article separates established RCN2 biology from unvalidated drug hypotheses and offers a practical framework for pathway-focused experiments.

• SNAI1–PIK3R2/p-EphA2 Signaling in Thymic Tumors

  2026-09-25

  A 2024 study identifies SNAI1 as a driver associated with invasiveness in thymic epithelial tumors and links it to EMT and cancer stem cell-like features. Combining tumor-expression analyses with functional experiments, the authors propose that SNAI1 transcriptionally regulates PIK3R2, which interacts with phosphorylated EphA2 and supports downstream GSK3β/β-catenin signaling.

• LY294002: Designing Better PI3K Experiments

  2026-09-24

  LY294002 can help translational researchers interrogate PI3K signaling—but meaningful conclusions depend on context, orthogonal readouts, and careful attention to its broader target profile. This article connects pathway biology with practical experimental design and clarifies what a microglial P2Y2 study can, and cannot, tell us about PI3K research.

• Anlotinib hydrochloride in Angiogenesis Assays

  2026-09-24

  Use Anlotinib hydrochloride to connect inhibition of VEGFR2, PDGFRβ, and FGFR1 with measurable endothelial migration and tube-formation outcomes. This workflow-focused guide explains how to select starting conditions, separate signaling effects from cytotoxicity, and troubleshoot variable angiogenesis assays.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-09-23

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based assays, including in situ hybridization and Northern blotting. It is intended for research use only; it is not validated for diagnostic, therapeutic, or clinical use.

• Cytosine Base Editing: Fidelity Before Translation

  2026-09-23

  Cytosine base editing can install precise point mutations without double-strand DNA breaks, but translational confidence depends on more than editing rate. This article connects whole-genome evidence, mRNA workflow design, product selection, and decision gates for responsible research use of EZ Cap™ CBEmax mRNA (m1Ψ).

• Grazoprevir/Elbasvir Therapy for HCV: Evidence Review

  2026-09-22

  The reference review explains how complementary NS3/4A and NS5A inhibition established an interferon-free, fixed-dose strategy for chronic hepatitis C. Its synthesis highlights high sustained virologic response rates, activity across important patient subgroups, and the need to interpret genotype, resistance, comorbidity, and drug-interaction data together.

• Nilotinib in Alzheimer’s Disease: What the 2024 Study Shows

  2026-09-22

  The 2024 Life study tested whether Nilotinib could alter amyloid-processing and mitochondrial-health markers in SH-SY5Y human neuroblastoma cells. Although the treatment changed selected protein levels, it did not produce a consistent neuroprotective expression profile, so the findings do not support efficacy for Alzheimer’s disease without further validation.

• PD 0332991: Separating Arrest from Cell Death

  2026-09-21

  PD 0332991 and Palbociclib HCl are powerful tools for studying CDK4/6-driven cell-cycle control. This guide explains how to distinguish cytostatic G1 arrest from genuine cell killing when designing cancer assays.

8167 records 1/545 page Next 12345 下5页 Last page